Whether a drug can effectively bind to its target protein, or how different parts of a virus or a cell interact, depends on processes taking place at the level of individual molecules. Their behaviour is determined not only by their shape, but also by the electrostatic forces acting between them. Understanding how these forces are distributed helps scientists explain why certain molecules attract each other, how they bind and how they interact.This is where the <a target="_blank" rel="noopener noreferrer" href="https://acc.biodata.ceitec.cz/">Atomic Charge Calculator (ACC)</a> comes in. Researchers at Masaryk University have been developing this computational tool for more than a decade. Its third and most advanced generation to date was developed at CEITEC Masaryk University and the Faculty of Science at Masaryk University, in collaboration with the Faculty of Informatics at Masaryk University and Palacký University Olomouc.ACC III calculates the electric charges of individual atoms and visualises their distribution directly within three-dimensional molecular structures. It brings together twenty different calculation methods in a single environment and can work with a wide range of molecules – from small organic compounds to proteins and other large biomolecular structures.A key advantage of Atomic Charge Calculator III is that it combines a broad range of computational methods with ease of access. Basic calculations can be performed directly in a web browser, with no need to install specialised software or register for an account. The resulting charges can be displayed directly on a 3D model of the molecule. For advanced users and large-scale analyses, the platform also supports automated data processing and allows its computational core to be run locally.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Co_pritahuje_molekuly_Nova_generace_nastroje_z_CEITEC_zviditelnuje_sily_mezi_atomy_d32d7bd2cd.jpg" alt="CEITEC/Biological Data Management and Analysis Core Facility: What Attracts Molecules? A New Generation of a CEITEC Tool Makes the Forces Between Atoms Visible: Oseltamivir bound to influenza virus neuraminidase (blue: positive partial charges, red: negative charges). A strong electrostatic interaction occurs between a negatively charged region of the drug and positively charged regions of the protein." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Co_pritahuje_molekuly_Nova_generace_nastroje_z_CEITEC_zviditelnuje_sily_mezi_atomy_d32d7bd2cd.jpg 140w," sizes="100vw" width="1600" height="1786"><h3>Why are scientists interested in the electric charges of atoms?</h3>Electrons are not distributed evenly within molecules. Individual atoms can therefore carry different partial electric charges. These charges play an important role in determining how molecules behave towards their surroundings and towards one another.Positively and negatively charged regions of molecules can attract each other, while regions with the same charge repel each other. The distribution of these charges therefore helps determine which molecules approach each other, how they orient themselves and how strongly they may bind. In biology, this is important, for example, in molecular recognition or when a drug binds to its target protein. Understanding partial charges therefore helps scientists gain insight into the interactions underlying the behaviour of many molecular systems.There is, however, no single universal way to determine partial charges. Different computational methods can produce different values, and the choice of method also depends on how the results will be used. Accurate quantum-chemical calculations can also become very computationally demanding when large numbers of structures are involved. ACC III therefore brings together empirical methods that allow these calculations to be performed more quickly and on a large scale.“From the outset, we designed ACC III to make calculating partial atomic charges as straightforward as possible. Users do not need to install anything or deal with complicated settings – they simply upload a molecule and start the calculation with a single click. The application then suggests suitable methods from the twenty available and can handle both small molecules and large biomolecular structures,” says <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/tomas-racek-ph-d/u94476?page=publication">Tomáš Raček</a>, who has been developing and maintaining ACC since 2018.<h3>How an antiviral drug binds to an influenza virus protein</h3>The authors demonstrate what charge distribution can reveal using the well-known antiviral drug oseltamivir, marketed as Tamiflu. The drug binds to neuraminidase, a protein of the influenza A virus. ACC III can show directly within the three-dimensional structure where positive and negative partial charges are located and how they contribute to the interaction between the drug and the protein.“The example of oseltamivir clearly shows why it is useful not only to calculate the charges, but also to visualise them directly within the structure. This allows us to see which parts of the two molecules interact electrostatically. The same approach can be used to study many other molecular systems,” explains Tomáš Raček.ACC III is not limited to small molecules. It can also work with proteins and other large biomolecular structures. The authors demonstrate this using a second example: the SARS-CoV-2 pore complex. Coronaviruses form these pores during replication in infected cells and use them to transport viral RNA across membranes. Visualising partial charges helps distinguish the parts of the complex that pass through the non-polar environment of the membrane from its more highly charged regions.<h3>From calculation straight to a 3D model</h3>The new generation of the Atomic Charge Calculator also offers more advanced visualisation. It uses Mol*, which allows calculated charges to be mapped directly onto a three-dimensional structure and explored interactively. A visualisation created using ACC III was also selected for the cover of the special Nucleic Acids Research Web Server Issue. Created by Tomáš Raček, the cover image shows the distribution of partial charges in a membrane protein system.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CEITEC_Co_pritahuje_molekuly_Nova_generace_nastroje_z_CEITEC_zviditelnuje_sily_mezi_atomy_3_85cc310925.jpeg" alt="CEITEC/Oxford University Press: What Attracts Molecules? A New Generation of a CEITEC Tool Makes the Forces Between Atoms Visible: Cover page in Nucleic Acids Research journal." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CEITEC_Co_pritahuje_molekuly_Nova_generace_nastroje_z_CEITEC_zviditelnuje_sily_mezi_atomy_3_85cc310925.jpeg 124w," sizes="100vw" width="1600" height="2011">Results can be downloaded in several standard formats and, for the first time, stored directly in the mmCIF format commonly used for three-dimensional biomolecular structures. Information about the structure and its calculated charges can therefore remain together in a single file and be used by other tools.For researchers who need to process large numbers of structures, ACC III also provides an API and a computational core that can be run locally. The platform can therefore be used both for individual calculations through its web interface and as part of larger automated analyses.<h3>More than a decade of development</h3>Scientists introduced the first Atomic Charge Calculator in 2015, followed by its second generation in 2020. In the meantime, the team also developed specialised tools: PDBCharges for structures from the Protein Data Bank and AlphaCharges for structures from the AlphaFold Database.“The Atomic Charge Calculator was never a one-off project,” says <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/prof-radka-svobodova-ph-d/u17518?page=publication">Radka Svobodová</a>, Head of the Biological Data Management and Analysis Core Facility at CEITEC Masaryk University. “For more than a decade, we have been continuously developing tools that respond both to new possibilities in structural bioinformatics and to the needs of their users. The third generation combines straightforward web-based use with capabilities that are important for the automated processing of large numbers of molecular structures.”<blockquote>Atomic Charge Calculator III is freely available through its web interface and does not require registration for basic use. Its development was supported by the ELIXIR CZ research infrastructure.</blockquote><h5>The authors presented the new generation of the tool in <a target="_blank" rel="noopener noreferrer" href="https://academic.oup.com/nar/article/54/W1/W211/8662890">Nucleic Acids Research</a>.</h5>

What Attracts Molecules? A New Generation of a CEITEC Tool Makes the Forces Between Atoms Visible 

Not every concentration job can tolerate heat — and not every concentrator that handles heat well can handle cold. <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2441">Refrigerated centrifugal vacuum concentrators</a> exist for a specific reason: proteins, RNA, enzymes, and synthetic peptides degrade quickly under thermal stress, and standard concentrators that rely on heat alone can compromise sample integrity before evaporation finishes. We compared two of the leading refrigerated systems — the Labconco Refrigerated CentriVap and the <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/products/2611">Thermo Fisher Refrigerated SpeedVac SRF110</a> — to see how they stack up for labs where sample preservation is non-negotiable.<blockquote><a target="_blank" rel="noopener noreferrer" href="https://explore.organomation.com/labconco-refrigerated-centrivap-vs-thermo-fisher-refrigerated-speedvac">Download the full comparison with pricing here!</a></blockquote><h3>The Problem Refrigeration Actually Solves</h3>It's a detail that gets lost in most spec-sheet comparisons: running a<a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/lcms/products?manufacturerItems=540&amp;search=centrivap"> vacuum concentrator </a>without temperature control can cause a sample to over-cool itself. As solvent evaporates under vacuum, the process pulls latent heat from the sample — the same evaporative cooling effect that makes sweat feel cold on skin. For a heat-stable solvent, that's irrelevant. For a temperature-sensitive biomolecule, it can drop the sample low enough to risk unwanted freezing or sublimation mid-run. Labconco's own engineering notes for the Refrigerated CentriVap describe this directly: the unit pairs a refrigeration system with a heater so operators can hold a precise set-point temperature and avoid sublimated samples caused by evaporative cooling. That's the whole reason this product category exists, and it's worth understanding before comparing specs line by line.<h3>Price: A Wider Gap at the High End</h3>The Labconco Refrigerated CentriVap is typically priced around $13,000 USD. The Thermo Fisher SRF110 runs higher, generally $15,000–$17,000 USD, and that's before factoring in the modular kit components — Thermo Fisher sells the SRF110 with a separate vacuum system, rotor, vapor trap, and heat transfer fluid bundled into the total kit price. The price gap between these two refrigerated units is proportionally larger than what we found comparing their non-refrigerated counterparts, which makes the value case for the CentriVap even more pronounced at this tier.<h3>Capacity: The Difference That Matters Most Right Now</h3>This is where the two systems really separate, and it lines up with where lab demand is heading. The Refrigerated CentriVap processes up to 312 samples per run; the SRF110 tops out at 132. Both handle volumes up to 50 mL, so this isn't a volume trade-off the way it was in our earlier comparison — it's a straight throughput advantage for the CentriVap.That gap matters because<a target="_blank" rel="noopener noreferrer" href="https://peptidestaff.com/industry-trends/peptide-therapy-market-forecast-2026/"> peptide-based therapeutics </a>have become one of the fastest-growing classes of drugs in the pharmaceutical industry, and manufacturing capacity — not demand — is widely cited as the primary bottleneck holding the sector back. <a target="_blank" rel="noopener noreferrer" href="https://labrulez.com/en-us/all/article/7541">GLP-1 programs</a> in particular are pushing <a target="_blank" rel="noopener noreferrer" href="https://www.bachem.com/knowledge-center/glp-1-demand-for-peptide-manufacturers/">peptide manufacturers</a> toward industrialized, large-scale production platforms rather than one-off batch work. <a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/">Sample prep equipment</a> sits squarely inside that bottleneck: every purification run, HPLC fraction, and concentration step has to scale alongside the chemistry. A concentrator that processes more than double the samples per run, like the Refrigerated CentriVap, is a meaningfully different proposition for a peptide synthesis or purification lab than it would have been five years ago.<h3>Temperature Range: How Cold You Can Go</h3>The CentriVap's refrigeration reaches as low as -10°C; the SRF110 bottoms out at -4°C. Both units heat up to +100°C. That six-degree gap on the cold end isn't dramatic on paper, but for the most heat-labile peptides and enzymes, the lower floor gives operators more margin before a sample is at risk — particularly during longer runs where evaporative cooling has more time to compound any thermal load on the sample.<h3>Vortex Speed and Mechanical Flexibility</h3>The CentriVap offers an adjustable vortex range from 500 to 1,800 rpm, while the SRF110 runs up to 1,725 rpm. The CentriVap's lower floor is the more useful distinction here — fragile, large, or shear-sensitive samples (think intact proteins or larger peptide constructs) sometimes need to run at reduced rotor speed to avoid mechanical stress, and the CentriVap gives operators that headroom on both ends rather than just a ceiling.<h3>Lid Material: Visibility vs. Durability</h3>The Refrigerated CentriVap uses a glass lid, letting operators see into the chamber during a run. The SRF110 uses an epoxy-coated aluminum lid, which trades visibility for added durability. For labs running visually distinct sample batches — colored buffers, multiple project codes, HPLC fractions pulled at different time points — the ability to glance at the chamber without interrupting a run has real workflow value, especially in a core facility setting where one instrument serves multiple research groups.<h3>What This Means for Core Facilities</h3>Shared instrumentation cores feel throughput and cold-temperature constraints differently than a single-PI lab does. A<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/an-appreciation-for-academic-core-labs"> core running samples from multiple research groups </a>— some doing routine RNA cleanup, others running heat-labile peptide fractions from an HPLC purification step — needs an instrument that won't bottleneck on either axis. The CentriVap's combination of higher per-run capacity and a lower refrigeration floor gives a shared facility more room to serve mixed workloads without forcing every group onto the same conservative settings a less flexible unit would require.<h3>Built for the Same Footprint</h3>Both units are sized for fume hood placement, with the CentriVap measuring 15.0 x 27.2 x 13.9 inches against the SRF110's 16.62 x 25 x 13.75 inches — close enough that floor planning isn't a deciding factor either way. Both carry standard one-year warranties.<h3>The Bottom Line</h3>For labs concentrating proteins, RNA, enzymes, or peptide fractions at scale — particularly anyone supporting peptide therapeutic development, where production capacity is already the limiting factor industry-wide — the Labconco Refrigerated CentriVap's combination of higher throughput, lower cold-temperature floor, and lower price makes it the stronger fit. The SRF110 remains a capable option for labs with smaller batch sizes already standardized on Thermo Fisher's modular vacuum ecosystem.Organomation distributes the full Labconco CentriVap line, including the Refrigerated and Refrigerated Pro models. Contact our team at sales@organomation.com to talk through rotor configuration, cold trap pairing, and throughput planning for your lab.&nbsp;<blockquote><h5><a target="_blank" rel="noopener noreferrer" href="https://explore.organomation.com/labconco-refrigerated-centrivap-vs-thermo-fisher-refrigerated-speedvac">Download the full comparison with pricing here!</a></h5></blockquote>

Refrigerated SpeedVac SRF110 vs. CentriVap - Why Sample Capacity Matters More Than Ever for Peptide and Protein Labs

What if you could assess a tumor's metastatic potential — without extensive sample prep — directly from tissue? Rachel Wood is working on exactly that.Rachel Wood is a PhD candidate at Queen's University (Kingston, Ontario),&nbsp;working jointly in the labs of Dr. Richard Oleschuk (Chemistry) and Dr. Chris&nbsp;Nicoll (Pathology &amp; Molecular Medicine). Her research applies Ambient Ionization Mass Spectrometry — specifically the Liquid Microjunction Surface Sampling Probe &nbsp;(LMJ-SSP) and Desorption Electrospray Ionization (DESI) — to profile the metabolomics of non-metastatic and metastatic clear cell Renal Cell Carcinoma (ccRCC) cell lines. The long-term goal: a rapid, minimally invasive MS-based prognostic tool for kidney cancer.This is the first reported use of LMJ-SSP to assess metastatic status in ccRCC —&nbsp;and early PCA results are already showing distinct separation between cell line&nbsp; profiles.<h5>In this episode, David and Rachel cover:</h5><ul><li>Why ccRCC is such a resistant biomarker problem despite active genomic, proteomic, and metabolomic research</li><li>The clinical stakes of "diagnosed by accident" — and what a prognostic biomarker actually needs to do for a clinician</li><li>How AIMS complements (not replaces) LC-MS in a discovery-phase cancer workflow</li><li>LMJ-SSP vs. DESI: what each technique sees that the other misses, including spatial resolution differences (~1mm vs. ~50µm)</li><li>Why Rachel runs LMJ-SSP on both a triple quad and a Q-TOF — and what each instrument contributes to the same research question</li><li>How her lab repurposed a 3D printer as a custom automated XYZ sampling stage with 50µm movement precision</li><li>Managing high-dimensional metabolomics data across two polarities, two cell lines, and two mass analyzers — the pipeline explained</li><li>What unsupervised machine learning (PCA) showed in early results</li><li>The path from cell lines to excised tumor tissue to, ultimately, liquid biopsies</li><li>Advice for analytical chemists considering work at the chemistry–oncology interface</li></ul><h3>Video Transcription</h3>Kidney cancer remains a difficult biomarker problem, particularly when researchers try to distinguish tumors that are likely to behave aggressively from those that are not. In a recent episode of Concentrating on Chromatography, PhD researcher Rachel Wood discussed how she is combining rapid ambient ionization mass spectrometry, LMJ-SSP, DESI, multivariate data analysis, and conventional LC-MS workflows to investigate the molecular differences associated with clear cell renal cell carcinoma and its metastatic potential.<h4>Returning to the research question that started it all</h4>Wood first encountered kidney cancer research during her undergraduate studies. Although she later moved into a more instrumentation-focused master’s project involving breast cancer, the subject of kidney cancer remained unfinished business.When the opportunity arose to choose a PhD project, she returned to the field that had originally sparked her interest in research. She is now conducting her doctoral work at Queen’s University in Kingston, Ontario, in an interdisciplinary environment spanning chemistry, pathology, molecular medicine, computer science, and clinical research.<h4>Why clear cell renal cell carcinoma is such a difficult biomarker problem</h4>Wood’s research focuses on clear cell renal cell carcinoma (ccRCC), which represents the majority of kidney cancer cases discussed in the interview.The difficulty is not a lack of research effort. Genomics, proteomics, and metabolomics studies have all produced promising biomarker candidates. The challenge is that different studies often identify different sets of markers, with relatively little overlap between them.Patient-to-patient biological variability further complicates the picture. A candidate biomarker panel that performs well in one cohort may not reproduce equally well in another. Selecting which features deserve further investigation therefore becomes a major analytical and biological challenge.<h4>From incidental diagnosis to prognostic information</h4>Another difficulty is the way kidney cancer is often discovered.Rather than being detected through a dedicated screening program, tumors may be found incidentally during imaging performed for another reason. According to Wood, the ideal solution would be a diagnostic biomarker capable of detecting kidney cancer early. Such a marker is not currently available within the scope of the work she described.That places additional importance on prognostic biomarkers. Once a tumor has been detected, clinicians need as much information as possible about how aggressive it may be and how likely it is to progress.Wood’s current work is therefore not attempting to declare directly that a particular patient has metastatic disease. Instead, the goal is to understand what changes biologically as a tumor moves from a less aggressive to a more aggressive state.That means asking which molecular pathways change, which mechanisms become altered, and which analytes may eventually provide useful indicators of tumor behavior.<h4>AIMS and LC-MS answer different questions</h4>A central theme of the interview was the relationship between rapid ambient ionization mass spectrometry and conventional LC-MS.Wood is clear that AIMS is not intended to replace LC-MS. Instead, she sees the two approaches as complementary.AIMS provides a rapid way to obtain a broad molecular overview of a sample with minimal preparation. This makes it especially useful during the discovery phase, when the goal is to gather as much molecular information as possible and identify features that distinguish biological groups.LC-MS then becomes valuable when those features need to be separated, characterized more carefully, and quantified with greater confidence.In Wood’s workflow, rapid MS screening can therefore help identify which analytes deserve closer attention before more targeted LC-MS investigations are performed.<h4>What “minimal sample preparation” actually means</h4>The amount of sample preparation required depends strongly on the type of material being analyzed.Wood currently works mainly with cultured human cell lines, which means much of the preparation begins with growing the cells themselves. Depending on the experiment, the cells may then be chemically lysed or subjected to fixation, paraffin embedding, and sectioning before analysis by LMJ-SSP or DESI.She also notes that the possibilities would be different for freshly excised tumor material. In an appropriate perioperative or biosafety laboratory setting, LMJ-SSP could potentially be used to analyze tumor margins more directly.The practical meaning of “minimal preparation” is therefore highly dependent on the sample and the analytical question being asked.<h4>Why combine LMJ-SSP and DESI?</h4>Rather than choosing between LMJ-SSP and DESI, Wood uses the two approaches because they provide different types of information.LMJ-SSP offers rapid, localized analysis and can accommodate samples with uneven surface topography, which is particularly useful for excised tissue.DESI, by contrast, provides substantially higher spatial resolution. In the workflow described in the interview, DESI can achieve spatial resolution on the order of tens of micrometers, whereas LMJ-SSP operates at a much larger sampling scale depending on probe design.That higher spatial resolution is important when moving from simplified cell-line models toward actual tumor tissue, where the molecular organization of different regions may reveal biologically relevant differences.Combining both techniques therefore enables researchers to balance speed, surface compatibility, and spatial information.<h4>Two mass analyzers for two parts of the same problem</h4>Wood also uses two different mass spectrometers in her LMJ-SSP work.Most of the discovery work is carried out using a triple quadrupole mass spectrometer, particularly because her project focuses strongly on lower-mass analytes and small molecules.Once statistically important analytes have been identified, a Q-TOF instrument can be used for MS/MS experiments and tentative structural identification.The two instruments therefore address different stages of the workflow: one supports broad discovery and comparison, while the other provides additional structural information needed to connect selected features with possible metabolic pathways.<h4>Turning a 3D printer into an automated sampling platform</h4>One of the most unusual elements of the project is the automated sampling system used with LMJ-SSP.Historically, LMJ-SSP measurements could be performed manually or with custom-built XYZ positioning stages. Wood’s laboratory instead adapted a 3D printer into an automated positioning system.Custom software controls the printer and moves the sampling probe with precise control over its X, Y, and Z positions. According to Wood, the system enables movements down to approximately 50 µm and also controls parameters such as the contact time between the probe and sample and the delay between consecutive sampling events.This level of automation improves reproducibility because variables that would otherwise depend on manual operation can be controlled systematically.Even the Z-position can be programmed, allowing the probe to operate at constant or varying heights depending on the sample surface.<h4>Managing high-dimensional MS data</h4>The experimental design creates a large data-analysis challenge.Wood is working with multiple cell lines, both ionization polarities, and more than one mass analyzer. To maintain traceability, she analyzes the data in clearly defined subsets.A typical workflow might begin with one mass analyzer and one polarity. Within that condition, the lower-aggressiveness and higher-aggressiveness cell models can then be compared directly.The data processing pipeline includes steps such as:<ul><li>binning,</li><li>normalization,</li><li>transformation,</li><li>dimensionality reduction,</li><li>identification of discriminating molecular features.</li></ul>Once relevant features are identified, MS/MS analysis can be used to investigate them further. The same process is then repeated across other polarities and instruments.<h4>Unsupervised machine learning reveals distinct molecular profiles</h4>Machine learning is particularly valuable because the AIMS datasets are highly dimensional, containing very large numbers of molecular features across multiple samples.Wood’s initial analysis has included principal component analysis (PCA), an unsupervised dimensionality-reduction technique.The early results are encouraging: the non-metastatic and metastatic cell-line models separate clearly in PCA space.That does not itself identify a definitive biomarker panel, but it indicates that the two biological states have distinguishable molecular profiles even though both belong to the same kidney cancer subtype.This provides an important foundation for identifying which specific metabolites or molecular pathways may be responsible for the separation.<h4>Testing LMJ-SSP for metastatic status</h4>A particularly novel aspect of Wood’s project is the use of LMJ-SSP to investigate differences associated with metastatic status.She had previously worked on distinguishing healthy and cancerous tissues, where the biological differences are relatively large. Comparing two states within the same cancer type is more demanding because the molecular changes may be much subtler.The scientific motivation, however, is strong. Tumors discovered at later stages carry greater concern for metastatic progression, making it important to understand the molecular changes associated with increasingly aggressive behavior.For Wood, this made the methodological risk worthwhile: the analytical challenge directly addresses an area where better prognostic information could ultimately have clinical value.<h4>A long-term goal: rapid MS-based prognostic testing</h4>The long-term vision extends beyond cell-line research.Wood is interested in whether rapid, minimally invasive mass spectrometry could eventually contribute to clinical decision-making.One possibility would be identifying a diagnostic biomarker in a liquid biopsy, potentially using blood or urine. A urine-based marker capable of contributing to earlier detection would be particularly attractive for kidney cancer.For prognostic applications, the goal would be slightly different. Once a tumor is discovered, molecular information could help characterize its likely behavior and provide clinicians with additional evidence when deciding between immediate treatment, surgery, or other management strategies.Wood emphasizes that such a tool would not replace standard clinical workflows. Instead, it would provide additional molecular information to complement existing diagnostic and pathological approaches.<h4>Why interdisciplinary work matters</h4>Throughout the interview, Wood repeatedly returns to the importance of collaboration.Her research sits at the intersection of analytical chemistry, pathology, oncology, computation, and clinical medicine. No single researcher can remain equally current in all of these fields.Working closely with pathologists, computer scientists, surgeons, medical students, and other specialists therefore provides both scientific expertise and a way to stay connected with developments outside one’s immediate discipline.For Wood, the biological context has also changed how she thinks about analytical chemistry. Developing a new instrument or method is important, but understanding who may ultimately benefit from that analytical capability makes the research more meaningful.That patient-centered perspective is now an integral part of how she approaches the project.<h4>An intersection full of opportunities</h4>Wood describes the interface between analytical chemistry and oncology as an especially exciting area for young researchers.The work can range from troubleshooting instrumentation to interpreting pathology, developing statistical methods, and collaborating across disciplines. That diversity creates constant opportunities to learn and to apply analytical chemistry to clinically relevant questions.Her project illustrates that modern mass spectrometry research is increasingly about more than generating spectra. It involves connecting instrumentation, spatial sampling, multivariate statistics, machine learning, biological interpretation, and clinical needs into a single analytical strategy.And in kidney cancer, where reliable prognostic biomarkers remain difficult to establish, that integrated approach may be particularly valuable.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

AIMS vs. LC-MS for Cancer Diagnostics: ccRCC Metabolomics with Rachel Wood

Article

Product

Scientists

Interview

Science and research

Video

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Separation Science

Metrohm

Technology Networks

Bruker

Phenomenex

Thermo Fisher Scientific

SelectScience

SCIEX

Evosep Biosystems

Identifying small-molecule binders for complex biological targets remains a major challenge in early drug discovery, particularly when working with membrane proteins or large protein complexes. Mass spectrometry (MS)–based screening approaches are increasingly used to address these challenges, but they can present technical limitations and experimental design considerations.In this webinar, Dr. Johann Stojko, experienced biophysicist at Novalix, will present integrated workflows that combine covalent fragment screening and non-covalent binder detection to support hit discovery and validation.Through practical case studies, attendees will see how complementary MS strategies can help improve confidence in screening results and accelerate progression from hit identification to lead optimization.<h4>Attend this webinar to:</h4><ul><li>Understand the screening approaches developed at Novalix</li><li>Explore workflows used to address challenging targets, including membrane proteins and protein complexes</li><li>Identify the limitations and advantages of each technique</li><li>Learn how experimental design and appropriate controls can improve confidence in MS screening results</li></ul><blockquote>Speaker:&nbsp;Johann Stojko, PhD (Senior Project Manager, Novalix) Speaker:&nbsp;François Debaene (Head of Mass Spectrometry, Novalix)</blockquote>

Technology Networks: Mass Spectrometry in Drug Discovery: Covalent and Non-Covalent Screening Applications

Mass Spectrometry in Drug Discovery: Covalent and Non-Covalent Screening Applications

Integrated workflows that combine covalent fragment screening and non-covalent binder detection to support hit discovery and validation.

Covalent and Non-Covalent Screening Applications

Crosslinking mass spectrometry (XL-MS) is transforming how researchers map protein–protein and protein–nucleic acid interactions, delivering structural insights at peptide-level resolution. But achieving high-confidence results requires an optimized, end-to-end workflow.Join us for this webinar to learn how to implement practical XL-MS strategies that improve crosslink detection, sensitivity, and data confidence. Our expert speaker will walk through best practices across sample preparation, advanced LC-MS acquisition, and data analysis using Thermo Scientific™ Proteome Discoverer™ software with the XlinkX algorithm.<h4>You Will Learn</h4><ul><li>How to optimize sample preparation and enrichment strategies to enhance crosslink identification</li><li>Advanced LC-MS acquisition strategies, including real-time library search (RTLS) for improved sensitivity</li><li>Best practices for analyzing crosslinking data in Proteome Discoverer software with XlinkX</li><li>Approaches for visualizing and interpreting interaction data to support structural insights</li><li>Introduction to NuXL workflows for profiling protein–nucleic acid interactions and expanding interactomics capabilities</li></ul><blockquote>Speaker: Yi He (Marketing Manager, Thermo Fisher Scientific)Dr. Yi He earned her PhD in Analytical Chemistry from Indiana University Bloomington. She was a research fellow and instructor at the University of Washington, applying structural proteomics to cardiovascular disease and diabetes research. In 2022, she joined Thermo Fisher Scientific as Vertical Marketing Manager for Structural Biology, focusing on crosslinking MS, protein structure, and protein–nucleic acid interactions.Moderator: Weijing Liu (Senior Marketing Manager, Thermo Fisher Scientific)</blockquote>

Thermo Fisher Scientific: From Sample to Structure: Crosslinking MS Made Practical

From Sample to Structure: Crosslinking MS Made Practical - Part 1

Learn how to implement practical XL-MS strategies that improve crosslink detection, sensitivity, and data confidence.

Crosslinking MS Made Practical

Crosslinking mass spectrometry (XL-MS) is transforming how researchers map protein–protein and protein–nucleic acid interactions, delivering structural insights at peptide-level resolution. But achieving high-confidence results requires an optimized, end-to-end workflow.Join us for this webinar to learn how to implement practical XL-MS strategies that improve crosslink detection, sensitivity, and data confidence. Our expert speaker will walk through best practices across sample preparation, advanced LC-MS acquisition, and data analysis using Thermo Scientific™ Proteome Discoverer™ software with the XlinkX algorithm.<h4>You Will Learn</h4><ul><li>How to optimize sample preparation and enrichment strategies to enhance crosslink identification</li><li>Advanced LC-MS acquisition strategies, including real-time library search (RTLS) for improved sensitivity</li><li>Best practices for analyzing crosslinking data in Proteome Discoverer software with XlinkX</li><li>Approaches for visualizing and interpreting interaction data to support structural insights</li><li>Introduction to NuXL workflows for profiling protein–nucleic acid interactions and expanding interactomics capabilities</li></ul><blockquote>Speaker: Yi He (Marketing Manager, Thermo Fisher Scientific)Dr. Yi He earned her PhD in Analytical Chemistry from Indiana University Bloomington. She was a research fellow and instructor at the University of Washington, applying structural proteomics to cardiovascular disease and diabetes research. In 2022, she joined Thermo Fisher Scientific as Vertical Marketing Manager for Structural Biology, focusing on crosslinking MS, protein structure, and protein–nucleic acid interactions.Moderator: Weijing Liu (Senior Marketing Manager, Thermo Fisher Scientific)</blockquote>

From Sample to Structure: Crosslinking MS Made Practical - Part 2

Crosslinking MS Made Practical - Part 2

Purifying synthetic peptides is a critical step in developing advanced biotherapeutics like GLP-1 receptor agonists. Even with precise synthesis, impurities such as deletions, truncations, and chemical modifications are unavoidable, making purification essential for achieving high purity, optimal yield, and cost efficiency.Join this SelectScience® webinar to discover why reversed-phase chromatography (RP) remains the gold standard for peptide purification and analysis. This session will be led by Bill Warren, Principal Consultant Product Manager, Waters Corporation, who has extensive experience with chromatography techniques for protein purification. He will guide you through the complete lab-scale purification process for a GLP-1 RA using optical detection, and will show how these strategies can be applied to other synthetic peptide modalities, including radio-labeled peptides, cyclic peptides, peptide antimicrobials, and more.<h4>Key learning objectives:</h4><ul><li>Understand strategies for developing analytical scale biotherapeutic peptide separations.</li><li>Learn techniques for lab-scale preparative synthetic peptide separations and fraction analysis.</li><li>Explore how reversed-phase mobile phase modifiers and chemistries impact peptide separation performance.</li><li>Gain practical troubleshooting tips for reversed-phase peptide separations.</li></ul><h4>Who should attend?</h4><ul><li>Biopharmaceutical and peptide research professionals, including academics and industry scientists.</li><li>Biopharma outsourcing partners, such as CDMOs, CMOs, and CROs.</li><li>Broader biopharmaceutical industry professionals involved in development, manufacturing, or research</li></ul><blockquote>Speaker:&nbsp;Bill Warren (Principal Consultant Product Manager, Waters Corporation)Bill Warren joined Waters Corporation as a senior applications chemist involved with the research and development of HPLC, FPLC, and capillary electrophoresis applications for the analysis and purification of proteins, peptides, and nucleic acids. He now acts as Principal Consultant Product Manager whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of biological molecules.Moderator: Olivia Long (Editorial Team, SelectScience)</blockquote>

Select Science: Why researchers turn to reversed phase chromatography when purifying GLP-1

Why researchers turn to reversed phase chromatography when purifying GLP-1

Understand strategies for developing analytical scale biotherapeutic peptide separations.

Why researchers turn to reversed phase chromatography

Along with gravimetry, titration is one of the oldest and most reliable quantitative analytical methods known. It is generally used as the primary reference method for other, mostly qualitative, analytical methods and it is indispensable for routine analysis in the laboratory.In this webinar, Robert Tobler, Senior Application Specialist Titration at Metrohm International Headquarters, will give you an introduction to the basics of titration. After a brief excursion into the theory, Robert will explain how to perform a titration step by step on a modern, automatic titrator with a photometric or an electrochemical sensor.During a Q&amp;A session at the end of the webinar you can ask Robert any question you may have about titration. Join us on 29 April; we are looking forward to welcoming you in this webinar!<h4>Key learnings of this webinar:</h4><ul><li>The most important measuring modes for potentiometric titration and application examples from various industries</li><li>How to optimize your titration results for higher accuracy and better reproducibility</li><li>Common mistakes and how you can avoid them</li><li>How to properly handle and take care of your electrodes</li></ul><h4>Who should attend?</h4><ul><li>Lab technicians, chemists, and everybody else using titration for their routine analytics.</li></ul><blockquote>Presenter: Robert Tobler (Senior Application Specialist Titration, Metrohm International Headquarters)After his apprenticeship as a chemical laboratory technician and further training as a biomedical analyst, Robert Tobler studied chemistry at the Zurich University of Applied Science in Waedenswil, Switzerland. He joined Metrohm in 2015 as an application specialist titration. Since then, Robert has become an expert in applied titration sharing his expertise through the global network of Metrohm subsidiaries.</blockquote>

Metrohm: The Basics of Titration explained

The Basics of Titration explained

In this webinar, Robert Tobler will give you an introduction to the basics of titration.

<div><div container-id="cq-colctrl-lt0" comp-id="A1"><div>Join us for two enlightening webinars aimed at advancing your laboratory work! These sessions are tailored for professionals navigating regulations such as pharmacopoeia and American Chemical Society (ACS) guidelines, or those working in QC labs where precision is paramount. Learn how to implement PFAS-tested consumables and compliant reagents can refine your analytical processes.<ul><li>April 28: Understanding Pharmacopoeia and ACS Compliance Discover the critical role of compliant reagents in your lab and learn how to ensure that your analyses meet regulatory standards.&nbsp;</li><li>April 30: Benefits of PFAS-Tested Consumables Gain insights into the importance of PFAS-tested additives and solvents for reliable analysis and their impact on the quality of your results.</li></ul>*Two sessions per day: Europe/Asia &amp; Americas time zones<h4>What You'll Gain</h4>Analytical Excellence Week 2026 is meticulously organized to empower professionals in analytical chemistry, particularly those in regulated pharmaceutical labs, industrial quality control labs, environmental labs, and other testing labs. This is your opportunity to hear from industry experts sharing valuable knowledge and best practices for better workflow strategies.<h4>April 30: Benefits of PFAS-Tested Consumables</h4><ul><li>Gain a clear understanding of PFAS regulatory guidelines</li><li>Learn the role of high-purity solvents and additives in preventing contamination</li><li>Ensure accurate and reliable PFAS analytical results</li></ul><h4>Who Should Attend:</h4>All professionals involved in pharmaceutical or chemical analysis laboratories. You'll take away actionable insights that can immediately improve your daily practices.Don't miss out on this chance to achieve greater analytical outcomes. Register now!<h5>Broadcasts</h5><ul><li>Europe / Asia Broadcast: 8 am BST (London) / &nbsp;9 am CEST (Paris/Berlin) / 12:30 pm IST (Mumbai) / 3 pm CST (Beijing) &nbsp;/ 4 pm JST (Tokyo)</li><li>Americas Broadcast: 9 am PDT (Los Angeles) / 11 am CDT (Chicago) / 12 pm EDT (New York) &nbsp;</li><li>Duration: Approximately 1 hour each day</li></ul><blockquote>Presenter: Bettina Straub-Jubb (Senior Global Product Manager Analytical Technolgies, Merck KGaA, Darmstadt, Germany)Bettina is a Senior Global Product Manager and Lead Expert for Titration at Merck KGaA, Darmstadt, Germany. With over 30 years of experience in instrumental analysis, diagnostics, and reference materials, she specializes in titration and Karl Fischer titration. She is dedicated to enhancing and streamlining titration processes, driving the development of innovative technologies, advancing applications and reagents, and providing expert support to both customers and colleagues.She works closely with quality control and application laboratories, as well as the Research and Development department, to ensure continuous improvement in titration methodologies. Bettina holds a degree in Chemical Technology from the University of Applied Sciences, Darmstadt, Germany, and is a qualified Medical Technical Laboratory Assistant from the Medical Technical Academy Esslingen, Germany.Presenter:&nbsp;Christian Roth (Senior Global Product Manager Inorganic Reagents, Merck KGaA, Darmstadt, Germany)Christian Roth is a Senior Product Manager for Classical Inorganics at Merck KGaA, Darmstadt, Germany, where he has dedicated over 25 years to managing a diverse portfolio that includes salts, acids, caustic alkalis, bases, metals, and metal oxides of analytical purity.With a degree in International Business Management, Christian combines his extensive technical knowledge with a strong foundation in global business strategies. His expertise ensures that the products under his purview not only meet but exceed the rigorous requirements of analytical laboratories, addressing critical chemical, regulatory, and safety standards, and ultimately delivering exceptional value to customers.Presenter:&nbsp;Dr. Patrik Appelblad (Fellow and Technical lead, Chemistry R&amp;D, &nbsp;Merck KGaA, Darmstadt, Germany)Patrik is passionate about simplifying science, advancing instrumental analysis, assisting the scientific community in solving problems, as well as sharing knowledge through modern channels and diverse methods. Holding a PhD in Analytical Chemistry from Umea University, Sweden, Patrik brings almost 25 years of experience from various R&amp;D and marketing roles within the company. This extensive background equips him well as a technical lead and spokesperson on a range of topics, including PFAS Testing.Presenter:&nbsp;Patric Klein (Senior Global Product Manager; Organic and Inorganics Instrumental Analysis, Merck KGaA, Darmstadt, Germany)Patric Klein is a Senior Global Product Manager for Organic and Inorganic Reagents for Instrumental Analysis at Merck KGaA, Darmstadt, Germany. With over 20 years of experience at Merck, he has developed a strong expertise in managing high-purity reagents for instrumental analysis. His focus includes high-purity acids for AAS and ICP applications, as well as high-purity reagents for chromatography techniques such as IC, HPLC and LC-MS. Patric holds a Master's degree in Chemical Engineering which underpins his extensive knowledge and contributions to the field.Presenter:&nbsp;Lena Werner (Senior Global Product Manager Specialty Solvents, Merck KGaA, Darmstadt, Germany)Lena Werner is a Senior Global Product Manager for Specialty Solvents at Merck Life Science KGaA Darmstadt with nearly 20 years of experience in analytical solvents. She manages specialty solvents, including anhydrous, deuterated and PFAS-tested solvents. Lena holds a degree in Business Administration from Baden-Wuerttemberg Cooperative State University Mannheim, focusing on marketing, production, and logistics. At Merck, she has managed various product portfolios, including managing classical solvents for quality control and high-purity solvents for gas chromatography and spectroscopy.</blockquote></div></div></div>

SeparationScience: Analytical Excellence Week 2026

Analytical Excellence Week 2026: Part 2 - Benefits of PFAS-Tested Consumables

Gain insights into the importance of PFAS-tested additives and solvents for reliable analysis and their impact on the quality of your results.

Benefits of PFAS-Tested Consumables

<div>Integrating MALDI Imaging with spatial transcriptomics enables a more complete understanding of tissue organization by combining molecular distributions with high resolution gene expression patterns on the same tissue section. This multimodal approach provides deeper insight into cellular heterogeneity, functional states, and microenvironmental interactions, surpassing what either technique can reveal alone.This webinar brings together two perspectives that complete each other: a methodological view on how MALDI Imaging and spatial transcriptomics can be successfully integrated on a single tissue section, and an application focused perspective illustrating what new biological insights emerge once both data layers are aligned. Advances in sample compatibility, spatial coregistration, and data integration provide the technical foundation, while multimodal analyses of complex tissues reveal subtle molecular gradients, cell state variation, and region specific features relevant to disease mechanisms.More broadly, linking biochemical phenotypes with transcriptional programs supports improved interpretation of complex tissues, biomarker discovery, and mechanistic studies across spatial biology, demonstrating how methodological innovation and biological application jointly enable deeper scientific insight.<h4>Key Learning Objectives</h4><ul><li>Understand why integrating MALDI Imaging with spatial transcriptomics provides deeper biological context than either modality alone</li><li>Gain insight into how multimodal workflows can be implemented in practice</li><li>Learn how multimodal spatial readouts help uncover disease relevant molecular patterns and cellular heterogeneity</li><li>Discover how integrating molecular and transcriptomic information supports biomarker research and translational applications</li><li>See how complementary spatial readouts contribute to advanced applications across neuroscience, oncology, and broader spatial biology</li></ul><h4>Who Should Attend</h4><ul><li>Researchers in spatial biology, and multimodal imaging</li><li>Scientists studying tissue‑level molecular changes</li><li>Imaging mass spectrometry, transcriptomics, and single‑cell specialists exploring integrated workflows</li><li>Anyone interested in how MALDI Imaging contributes to next‑generation spatial multiomics and respective study design</li></ul><blockquote>Presenter: Eva Cuypers, Associate Professor, M4i - Maastricht for Imaging, Maastricht, Netherlands</blockquote></div>

Bruker: Bridging Molecules and Genes: Integrating MALDI Imaging and Spatial Transcriptomics on a Single Tissue Section

Bridging Molecules and Genes: Integrating MALDI Imaging and Spatial Transcriptomics on a Single Tissue Section

Learn how MALDI Imaging and spatial transcriptomics integration enables multimodal tissue analysis, biomarker discovery, and advanced spatial biology insights.

Integrating MALDI Imaging and Spatial Transcriptomics

Solving complex analytical challenges with QTRAP® workflows Modern analytical laboratories face increasing complexity — from trace‑level quantitation to challenging matrices, demanding regulations, and the need for unequivocal confirmation. Traditional triple quadrupole systems are often pushed to their limits.In this webinar, we introduce how QTRAP® transforms LC-MS/MS workflows by combining high-performance quantitation with unique MS³-level selectivity and full-scan spectral confirmation.Using real-world application examples—including polar pesticides, multiresidue pesticides, PFAS, mycotoxins, veterinary drugs, and forensic toxicology—we will demonstrate how QTRAP® workflows such as MRM³ and MRM-IDA-EPI deliver unmatched selectivity, eliminate interference, reduce background noise, and achieve LOQs not possible with conventional MRM.If you’ve ever wished for “more than a triple quad,” this session is for you.<h4>What to expect:</h4>During this webinar, attendees will:<ul><li>See side‑by‑side MRM vs. MRM³ chromatograms across many matrices</li><li>Understand when MRM is not enough — and how QTRAP® solves it</li><li>Learn how laboratories improved LOQs, selectivity, and confidence</li><li>Discover workflows that combine quantitation, confirmation, and screening in a single run</li><li>Receive a practical framework to assess which analytes benefit from QTRAP® functionalities</li></ul><h4>Key learning points:</h4>Participants will learn:<ul><li>QTRAP® overview</li><li>When and why MRM³ makes a difference</li><li>Real‑life application workflows</li><li>Practical method development tips</li></ul><h4>Who should attend:</h4>This webinar is designed for professionals working with complex LC‑MS/MS analyses, including:<ul><li>Food safety laboratories</li><li>Environmental laboratories</li><li>Forensic and toxicology labs</li><li>Analytical scientists and method developers</li><li>Research labs</li><li>Anyone using LC‑MS/MS who faces interferences, poor selectivity, or challenging matrices</li></ul>We will send you the recording after the event.<blockquote>Speaker: Dr. Jianru Stahl-ZengJianru is Senior Technical Marketing Manager. She has been part of SCIEX since 2001. She initially was part of the application support team and covered not only proteomics, but also small molecules applications. Jianru moved to technical marketing and focused on food and environmental applications. Since 2018 she has been managing the EMEA technical marketing team and projects. Jianru is also the Global Technical Leader for food and environmental applications.</blockquote>

SCIEX: Extending the power of LC‑MS/MS: advanced workflows with QTRAP®

Extending the power of LC‑MS/MS: advanced workflows with QTRAP®

How QTRAP LC-MS/MS workflows (MRM³, MRM-IDA-EPI) improve selectivity, lower LOQs, and deliver reliable results for food, environmental, and forensic analysis.

Power of LC‑MS/MS: advanced workflows with QTRAP

Learn the essentials of Size Exclusion Chromatography (SEC) for biopharma - a key technique for assessing molecular size, detecting aggregates, and evaluating product purity and stability.In this Fundamentals First Bio Series webinar, we’ll cover core SEC principles, instrumentation and column considerations, and best practices for method development and troubleshooting strategies.Through real-world examples - including monoclonal antibodies, biosimilars, AAVs, and nucleic acids - attendees will gain practical insights to improve method performance and confidence in their analytical results.<h5>Key Learning Points</h5><ul><li>Understand core SEC principles and key terminology.</li><li>Select appropriate instrumentation, columns, and method conditions.</li><li>Apply practical method optimization and troubleshooting best practices.</li><li>Review of common SEC applications for biologics characterization.</li></ul><h5>Who Should Attend</h5><ul><li>Analytical scientists and researchers working in biopharma development.</li><li>Process development and QC teams supporting biomolecule characterization.</li><li>Scientists seeking a foundational understanding of SEC methods and best practices.</li></ul><blockquote>Speaker: Zach Woodward (Senior Technical Specialist, Phenomenex)Zachary Woodward is a Senior Technical Specialist with Phenomenex, Inc, assisting laboratories with method development in the bio-pharma, environmental, and food industries. Zachary spent his formative years developing HPLC and GC methods with a pharmaceutical lab in Albany, NY, after which he developed HPLC and SPE methods in a clinical setting here in Southern California. Zachary received his B.Sci. in Chemistry from the College of William and Mary, was awarded his Master’s in Chemistry at San Diego State University, and is happy to speak with you today!</blockquote>

Phenomenex: Fundamentals First Bio Series – SEC for Biologics

Fundamentals First Bio Series – SEC for Biologics

Learn SEC fundamentals for biopharma, including method development, column selection, and applications in biologics characterization like mAbs and AAVs.

Discover how LC-MS is advancing biopharma workflows through scalable, high-throughput proteomics. This webinar will highlight recent developments in LC-MS-based approaches, including HCP analysis, untargeted quantification strategies, and scalable sample preparation, with a focus on robustness, reproducibility, and applicability in both research and regulated quality control environments.<h5>Prospective ICH Q2(R2)-aligned total-error validation of label-free untargeted proteomics for host cell protein quantification in biotherapeutics</h5><ul><li>Somar khalil, PhD, Principal Scientist, Analytical research &amp; Development, GSK</li></ul>Abstract to be announced

Evosep: Next-Gen HCP Analysis in Biopharma

Next-Gen HCP Analysis in Biopharma

Discover how LC-MS is advancing biopharma workflows through scalable, high-throughput proteomics. 